SAB Biotherapeutics, Inc. (SABS)
NCM · Healthcare · Biotechnology
$3.33
-1.48%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$282.2M
Exchange
NCM
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.7M | -12.7M | -15.8M | -20.0M |
| Net Income | -10.1M | 45.4M | -16.9M | -18.9M |
| Diluted EPS | $-1.09 | $-0.21 | $nan | $-0.35 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -28.9M | -38.1M | -42.9M | -49.0M |
| Net Income | -18.7M | -42.2M | -34.1M | 13.3M |
| Diluted EPS | $-4.31 | $-7.64 | $-3.68 | $nan |